investigation of genetic polymorphisms of cytochrome p450 2c19 in iranian patients with drug-eluting stents

Background: cytochrome p450 2c19 (cyp2c19) exhibits polymorphism, with about 21 known allelic variants. notably, the *17 allele is associated with increased enzymatic activity, culminating in enhanced cyp2c19 activity and the ultra-rapid metabolizer (um) phenotype. this genetic variation has a profound impact on an individual's response to a wide range of medications. the primary objective of this study was to ascertain the prevalence of the cyp2c19*17 allele among iranian patients who have received drug-eluting stents.methods: this study was conducted to examine the genetic polymorphism of the cyp2c19 enzyme in 100 patients with drug-eluting stents (dess) at imam hossein hospital, tehran, iran. all participants were selected based on pre-defined inclusion criteria. blood samples were obtained for dna extraction, and cyp2c19 genotypes were subsequently analyzed through polymerase chain reaction (pcr) and gel electrophoresis.results: the *17 polymorphism was detected in 11% of the cohort. of this group, 11 individuals were heterozygous carriers of the cyp2c19*17 allele, whereas the homozygous *17/*17 genotype was not observed in any participant.conclusion: our findings demonstrate a low prevalence of the cyp2c19*17 allele and an absence of the homozygous *17/*17 genotype in the iranian population. despite its lower prevalence compared to other populations, the clinical implications of this allele are still considered highly significant.